Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
US Market Access Strategy Consulting The new GLP-1 Mounjaro launched as a diabetes drug when only two out of the then nine GLP-1 therapies were indicated for obesity
On one hand, IBD can lead to dysregulation of adipokines, shifting the balance towards a pro-inflammatory state, on the other hand obesity and higher BMI are associated with higher risk of developing IBD and worse clinical outcomes, particularly for UC
Some people find it easier to remember a weekly injection, while others are more comfortable taking a daily tablet
Since it is primarily approved for diabetes and obesity, insurance companies may not cover it for RA, leaving patients to pay out of pocket
Common GLP-1 Inhibitors Some of the most commonly prescribed GLP-1 inhibitors include: Semaglutide (Ozempic, Wegovy, Rybelsus) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Tirzepatide (Mounjaro) Exenatide (Byetta, Bydureon) These medications are most commonly administered in the form of weekly injections, but there are a few oral formulations available on the market as well
If you are not sure where to start, take our personalised wellness quiz to narrow down the best fit
US$ 25.63
US$ 27.54
US$ 20.17
US$ 24.19
US$ 20.48
US$ 27.37
